Compare Penta Valent Tbk. (PEVE) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Penta Valent Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Penta Valent Tbk. trades at Rp308 (market cap 547.34B, 764.8K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Penta Valent Tbk. is far larger — about 5.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PEVE | SCPI | |
|---|---|---|
Market Cap | 547.34B | 104.4B |
Volume | 764.8K | — |
Lot | 7.65K | — |
Turnover | 234.84M | — |
Average Price | 307.07 | — |
Value | 234.84M | — |
Indicative Equilibrium Price | 308 | — |
Indicative Equilibrium Volume | 352 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Penta Valent Tbk.
PT Penta Valent Tbk (the Company) was established in 1968 in Jakarta, Indonesia under the name of CV Penta Valent, hereinafter, based on Notarial Deed No. 48 of Bebasa Daeng Lalo, S.H., dated August 16, 1972. The Company started its commercial operations in 1968. PT Tancorp Global Sentosa, a company incorporated in Indonesia, is the ultimate parent entity of the Company.
Read more on PEVE →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
